Insider · CIK 0001852075
Zavain Dar
director
Files at RXRX (RECURSION PHARMACEUTICALS, INC.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +4,607 | $0.00 | $0 | 245,371 | 10 d ago |
| Oct 1, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +2,941 | $0.00 | $0 | 138,758 | Oct 3, 2025 |
| Jul 1, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +2,924 | $0.00 | $0 | 135,817 | Jul 3, 2025 |
| Jun 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +22,016 | $0.00 | $0 | 132,893 | Jun 23, 2025 |
| Jun 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +44,031 | $0.00 | $0 | 44,031 | Jun 23, 2025 |
| Apr 1, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +2,745 | $0.00 | $0 | 110,877 | Apr 3, 2025 |
| Jan 2, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | AGrant or award Class A Common Stock | +1,907 | $0.00 | $0 | 108,132 | Jan 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.